Ward Bryan, Wettstein Vincent, Golding John, Corallo Giulia, Nuti Daniele, Trabalzini Franco, Mandala Marco
Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, USA.
Department of Otorhinolaryngology-Head and Neck Surgery, University Hospital Zurich, Zurich, Switzerland.
J Int Adv Otol. 2019 Apr;15(1):112-117. doi: 10.5152/iao.2019.5758.
The aim of the present study was to investigate current treatment practices and self-reported effectiveness in Ménière's disease.
Members of two Italian Ménière's disease support (n=170) with ≥6-month history of Ménière's disease were administered an online survey about recent treatments. Vertigo episode count, work absenteeism, and limitations in family life, social life, work, or travel as included in the Social Life and Work Impact of Dizziness Questionnaire before and after recent treatments were queried.
Twenty-four different treatments were reported for Ménière's disease, with dietary modifications (55%), diuretics (47%), and betahistine (41%) being the most common. The majority (71%) received multiple simultaneous treatments. Prior to the most recent treatments, 78%-89% of respondents indicated limitations in family or social life, work, or traveling. After their most recent treatment, respondents reported improvements in mean vertigo episode counts (5.7±7.6 vs. 2.6±4.6, p<0.001), days off work per month (10.1±9.2 vs. 4.2±6.7, p<0.001), and proportions indicating limitations in any functional measure assessed (p<0.05). These findings were consistent regardless of treatment approach (p<0.05 for all). Intratympanic gentamicin provided the greatest reductions in vertigo count, functional limitations, and work absenteeism (p<0.01 for all), as well as the fewest respondents reporting post-treatment functional limitations (16%-37%).
Despite many treatment approaches targeting different proposed pathophysiology for Ménière's disease in this cross-sectional survey, all treatments are reported as effective by patients. These findings support a prominent placebo effect in Ménière's disease and highlight challenges in studying treatment outcomes; there is a critical need to better understand Ménière's disease.
本研究旨在调查梅尼埃病当前的治疗方法及自我报告的疗效。
对170名患有梅尼埃病且病程≥6个月的意大利梅尼埃病支持组织成员进行了一项关于近期治疗的在线调查。询问了近期治疗前后《头晕对社交生活和工作的影响问卷》中包含的眩晕发作次数、旷工情况以及家庭生活、社交生活、工作或旅行方面的限制。
报告了24种不同的梅尼埃病治疗方法,其中饮食调整(55%)、利尿剂(47%)和倍他司汀(41%)最为常见。大多数(71%)同时接受多种治疗。在最近一次治疗之前,78%-89%的受访者表示在家庭或社交生活、工作或旅行方面存在限制。在最近一次治疗后,受访者报告平均眩晕发作次数有所改善(5.7±7.6对2.6±4.6,p<0.001),每月旷工天数(10.1±9.2对4.2±6.7,p<0.001),以及表示在任何评估的功能指标上存在限制的比例有所下降(p<0.05)。无论治疗方法如何,这些结果都是一致的(所有p<0.05)。鼓室内注射庆大霉素在眩晕次数、功能限制和旷工方面的减少最为显著(所有p<0.01),且报告治疗后功能受限的受访者最少(16%-37%)。
在这项横断面调查中,尽管有许多针对梅尼埃病不同病理生理学机制的治疗方法,但患者报告所有治疗方法均有效。这些发现支持梅尼埃病存在显著的安慰剂效应,并突出了研究治疗结果的挑战;迫切需要更好地了解梅尼埃病。